Immunodeficiency Virus (e.g., Hiv, Etc.) Patents (Class 424/208.1)
-
Patent number: 8394581Abstract: Since FIV-vaccinated cats produce antibodies against FIV, distinguishing them from FIV-infected cats is difficult by serological diagnostic methods using FIV and FIV-derived substances. The present invention enables tests for determining the presence or absence of a FIV vaccination history in a cat by detecting antibodies that are produced as a result of vaccination of a cat with an FIV vaccine, but not as a result of FIV infection. Using the methods of the present invention, whether an anti-FIV antibody-positive cat is infected with FIV or has been vaccinated can be conveniently distinguished.Type: GrantFiled: July 25, 2008Date of Patent: March 12, 2013Assignee: The Kitasato InstituteInventors: Tsutomu Hohdatsu, Kenji Motokawa, Hajime Kusuhara
-
Publication number: 20130058973Abstract: Native Tat, when administered to patients with HIV infection, or who are otherwise immunocompromised, is capable of restoring immune functions so as to recognise recall antigens, and to inhibit replication and key signs of HIV disease and other persistent infections and/or their progression.Type: ApplicationFiled: March 21, 2011Publication date: March 7, 2013Applicant: VAXXIT SRLInventor: Barbara Ensoli
-
Patent number: 8389275Abstract: The invention relates to fusion proteins comprising the amino acid sequence of at least three HIV proteins selected from Vif, Vpr, Vpu, Rev, and Tat or derivatives of the amino acid sequence of one or more of said proteins, wherein the fusion protein is not processed to individual HIV proteins having the natural N and C termini. The invention further concerns nucleic acids encoding said proteins, vectors comprising said nucleic acids, and methods for producing said proteins. The fusion protein, nucleic acids and vectors are usable as vaccines for the at least partial prophylaxis against HIV infections.Type: GrantFiled: February 14, 2012Date of Patent: March 5, 2013Assignee: Bavarian Nordic A/SInventors: Paul Howley, Sonja Leyrer, Eva Felder
-
Publication number: 20130052220Abstract: Disclosed is a vaccine that includes a dendritic cell loaded with a yeast vehicle and antigen. Also disclosed are methods of making the vaccine and using the vaccine to elicit cellular and humoral immune responses in a mammal. Additionally, a method to elicit an immune response by administration of a yeast vehicle and an antigen that is not complexed to the yeast vehicle is disclosed.Type: ApplicationFiled: June 12, 2012Publication date: February 28, 2013Applicants: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE, GLOBEIMMUNE, INC.Inventors: Richard C. Duke, Donald Bellgrau, Alex Franzusoff, Cara C. Wilson
-
Publication number: 20130052221Abstract: This invention provides a method of co-delivery of combination DNA and protein immunogenic compositions to enhance protective or therapeutic effects.Type: ApplicationFiled: February 25, 2011Publication date: February 28, 2013Applicant: The Govt. of the U.S, as represented by The Sec. of The Dept. of Health and Human ServicesInventors: Barbara K. Felber, George N. Pavlakis
-
Publication number: 20130045180Abstract: Improved vaccines which include a nucleotide sequence that encodes immunomodulating protein operably linked to regulatory elements are disclosed. The improved vaccines include DNA vaccines, recombinant vaccines for delivering foreign antigen and live attenuated vaccines. Methods of immunizing individuals are disclosed. Compositions for and methods of treating individuals with autoimmune diseases are disclosed.Type: ApplicationFiled: January 27, 2012Publication date: February 21, 2013Inventors: David B. Weiner, Jong J. Kim, Jeong-Im Sin
-
Publication number: 20130045229Abstract: Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.Type: ApplicationFiled: April 20, 2011Publication date: February 21, 2013Applicant: KINETA, INC.Inventors: Shawn P. Iadonato, Kristin Bedard
-
Publication number: 20130039944Abstract: Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.Type: ApplicationFiled: April 20, 2011Publication date: February 14, 2013Applicant: Kineta, Inc.Inventors: Shawn P. Iadonato, Kristin Bedard
-
Publication number: 20130039945Abstract: Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.Type: ApplicationFiled: April 20, 2011Publication date: February 14, 2013Applicant: Kineta, Inc.Inventors: Shawn P. Iadonato, Kristin Bedard
-
Patent number: 8367315Abstract: Azido-diarylpyrimidine (azido-DAPY) compounds, and compositions containing such compounds, are provided. In addition, methods of using azido-diarylpyrimidines to inactivate reverse transcriptases, prepare inactivated viruses, and treat or prevent viral infections are also provided.Type: GrantFiled: March 5, 2010Date of Patent: February 5, 2013Inventor: Adan Rios
-
Patent number: 8367068Abstract: A method to induce an immune response in a host in need thereof, comprises administering to the host, recombinant lentiviral vector particles comprising: a) a GAG polypeptide or a functional GAG-polypeptide derivative; b) a POL polypeptide or a functional POL-polypeptide derivative ; c) an ENV polypeptide or a functional ENV-polypeptide derivative; and d) a recombinant polynucleotide. The recombinant polynucleotide comprises a transgene placed under the control of regulatory signals for transcription and expression, regulatory signals, of lentiviral origin, for reverse transcription, expression and packaging, and a polynucleotide comprising a cis-acting central initiation region (cPPT) and a cis-acting termination region (CTS). The regions are of lentiviral origin and are inserted in a functional orientation with the regulatory signals of lentiviral origin. The polynucleotide forms a DNA triplex during reverse transcription.Type: GrantFiled: June 10, 2010Date of Patent: February 5, 2013Assignees: Institut Pasteur, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche ScientifiqueInventors: Pierre Charneau, Véronique Zennou, Hüseyin Firat
-
Patent number: 8367061Abstract: Novel anti-idiotype monoclonal antibodies are described which are capable of specifically reacting with the idiotype of human anti-gp120 antibodies, of inhibiting the binding between the gp120 antigen and human anti-gp120 antibodies, and of evoking a neutralising anti-gp120 immune response in an animal host to which they are administered. The anti-idiotype antibodies of the invention can be identified based on the amino acid sequences of the variable portions of their light and heavy chains. In addition, a method for obtaining a panel of anti-idiotype monoclonal antibodies, expression vectors and transformed host cells usable in a recombinant DNA procedure in order to generate the aforesaid anti-idiotype monoclonal antibodies, as well as the therapeutic, prophylactic and diagnostic use of such antibodies are disclosed.Type: GrantFiled: January 29, 2008Date of Patent: February 5, 2013Assignee: Pomona Ricera S.R.L.Inventors: Roberto Burioni, Massimo Clementi
-
Publication number: 20130004529Abstract: Improved anti-HIV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus sequences for HIV Subtype A Envelope protein, those having consensus sequences for HIV Subtype B Envelope protein, those having consensus sequences for HIV Subtype C Envelope protein, those having consensus sequences for HIV Subtype D Envelope protein, those having consensus sequences for HIV Subtype B consensus Nef-Rev protein, and those having consensus sequences form HIV Gag protein subtypes A, B, C and D. Improved anti-HPV immunogens and nucleic acid molecules that encode them; improved anti-HCV immunogens and nucleic acid molecules that encode them; improved hTERT immunogens and nucleic acid molecules that encode them; and improved anti-Influenza immunogens and nucleic acid molecules that encode them are disclosed as well methods of inducing an immune response in an individual against HIV, HPV, HCV, hTERT and Influenza are disclosed.Type: ApplicationFiled: April 27, 2012Publication date: January 3, 2013Inventors: David B. Weiner, Jian Yan, Dominick Laddy
-
Publication number: 20130004538Abstract: This document relates to compositions and methods for modulating an immune response. For example, compositions of immunostimulatory CpG oligonucleotides derived from retroviral genomes are provided.Type: ApplicationFiled: July 9, 2012Publication date: January 3, 2013Inventors: Lee A. Bulla, JR., Jeffrey Marcus Clark, Natalya Griko, Jian Sun, Ralph Clark
-
Publication number: 20120328641Abstract: Stabilized forms of gp120 polypeptide, nucleic acids encoding these stabilized forms, vectors comprising these nucleic acids, and methods of using these polypeptides, nucleic acids, vectors and host cells are disclosed. Crystal structures and computer systems including atomic coordinates for stabilized forms of gp120, and gp120 with an extended V3 loop, and methods of using these structures and computer systems are also disclosed.Type: ApplicationFiled: August 14, 2012Publication date: December 27, 2012Inventors: Peter Kwong, John Mascola, Gary Nabel, Richard Wyatt, Barna Dey, Ling Xu, Tongqing Zhou, Joseph Sodroski, Wen Yuan, Shi-Hua Xiang
-
Publication number: 20120328627Abstract: The present invention relates to a compound represented by formula (I): wherein all symbols are as defined here, a salt thereof, a solvate thereof, or a prodrug thereof. The compound of the present invention has an antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, rejection of transplanted organ, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy.Type: ApplicationFiled: August 28, 2012Publication date: December 27, 2012Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Masaya KOKUBO, Motoyuki Tanaka, Hiroshi Ochiai, Yoshikazu Takaoka, Shiro Shibayama
-
Patent number: 8338089Abstract: The present invention relates, e.g., to a method for inhibiting infectivity of a lentivirus (e.g., a lentivirus which expresses a Viral infectivity factor (Vif) protein), such as, e.g., SIV, SHIV and/or HIV, comprising contacting a cell which is producing the virus with an antiviral-effective amount of a membrane-permeable Zinc (Zn) chelator, wherein the antiviral-effective amount of the Zn chelator does not substantially inhibit proteins in the cell which contain Zn-binding motifs other than lentivirus Vif. Kits and pharmaceutical compositions are also disclosed, as is a method for identifying inhibitors of lentiviruses that target a specific zinc-binding motif of the lentivirus Vif protein.Type: GrantFiled: November 20, 2007Date of Patent: December 25, 2012Assignee: The Johns Hopkins UniversityInventors: Xiao-Fang Yu, Elana S. Erhlich, Xiao Zuoxiang
-
Patent number: 8338582Abstract: The present invention refers to new epitopes recognized by CD4+ T-lymphocytes. In addition, the present invention refers to the uses of such epitopes and their combinations, particularly in the treatment or prevention of disorders caused by the HIV-1 virus. The present invention also refers to a composition comprising said epitopes and the uses of said composition, particularly in the treatment or prevention of disorders caused by the HIV-1 virus. The present invention also refers to anti-HIV-1 prophylactic vaccines and therapeutic vaccines. Furthermore, the present invention refers to a method for the identification of epitopes and methods for treating or preventing an infection caused by the HIV-1 virus.Type: GrantFiled: March 5, 2008Date of Patent: December 25, 2012Assignees: Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, Fundacao Zerbini, Universidade de Sao Paulo-USPInventors: Edecio Cunha Neto, Jorge Elias Kalil Filho, Simone Goncalves Da Fonseca
-
Publication number: 20120321699Abstract: The present invention relates, in general, to an immunogen for HIV vaccination and, in particular, to a method of inducing the production of protective anti-HIV antibodies by targeting B cell germline and clone intermediates using a combination of HIV envelope and non-HIV immunogens. The invention also relates to compositions suitable for use in such a method.Type: ApplicationFiled: February 25, 2011Publication date: December 20, 2012Inventors: Barton F. Haynes, Hua-Xin Liao, Georgia Tomaras, Thomas B. Kepler, Kwan-Ki Hwang, S.Munir Alam, Yang Liu, T. Matt Holl, Guang Yang, Garnett Kelsoe, Mattia Bonsignori
-
Patent number: 8333980Abstract: The invention provides methods of modulating an immune response to a second antigen which entail administration of a first antigen and an immunostimulatory polynucleotide. Modulation of the immune response is generally manifested as stimulation of a Th1 response.Type: GrantFiled: November 13, 2008Date of Patent: December 18, 2012Assignee: Dynavax Technologies CorporationInventors: Gary Van Nest, Stephen F. Tuck, Joseph Eiden, Jr.
-
Publication number: 20120315296Abstract: The present invention relates to the design of gene transfer vectors and especially provides lentiviral gene transfer vectors suitable for either a unique administration or for iterative administration in a host, and to their medicinal application (such as vaccination against Immunodeficiency Virus, especially suitable in human hosts). Gene transfer vectors can be either integrative or non-integrative vectors. The invention encompasses prophylactic, therapeutic, symptomatic, and curative treatments of animals, including humans, as well as gene therapy and vaccination in vivo.Type: ApplicationFiled: April 23, 2012Publication date: December 13, 2012Inventors: Pierre Charneau, Anne-Sophie Beignon, Frederic Philippe Coutant, Karine Courbeyrette
-
Publication number: 20120308593Abstract: The disclosure relates to immunological compositions for vaccinating human beings against infection by the Human Immunodeficiency Virus (HIV).Type: ApplicationFiled: September 17, 2010Publication date: December 6, 2012Applicant: Sanofi Pasteur, Inc.Inventors: James T. Tartaglia, Sanjay Gurunathan, Jerome H. Kim, Donald Francis
-
Publication number: 20120308618Abstract: The invention discloses pharmaceutical compositions in liquid form comprising a peptide with the amino acid sequence KLKL5KLK and an oligodeoxynucleotide with the nucleic acid sequence (dIdC)13 and wherein the peptide and the oligodeoxynucleotide are present as sterile-filterable nanoparticles in the composition, thereby forming a suspension, characterized in that the mean particle size of the solid particles is less than 1 ?m.Type: ApplicationFiled: February 21, 2011Publication date: December 6, 2012Applicant: Intercell AGInventors: Benjamin Wizel, Karin Riedl, Karen Lingnau, Ursula Schlosser, Jürgen Wruss, Robert Schlegl, Michael Weber, Christoph Reinisch, Ljubomir Paucz, Christoph Klade, Jee Loon Look, Christian Ruiz, Robert Seid
-
Patent number: 8323661Abstract: The invention relates to novel insertion sites useful for the integration of HIV DNA sequences into the MVA genome, and to the resulting recombinant MVA derivatives.Type: GrantFiled: August 30, 2011Date of Patent: December 4, 2012Assignee: Bavarian Nordic A/SInventors: Paul Howley, Sonja Leyrer, Paul Chaplin, Eva Felder
-
Patent number: 8323662Abstract: Materials and methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein are provided. More specifically, methods for generating such materials include culturing in a culture medium including kifunensine a virus packaging cell with a lentiviral vector genome including a polynucleotide encoding an exogenous antigen, a polynucleotide encoding a Sindbis E2 glycoprotein that preferentially binds dendritic cells expressing DC-SIGN, and a polynucleotide encoding a Vpx protein or a Vpr protein that retains SAMHD1-inhibiting activity, followed by isolating a pseudotyped lentiviral vector particle that preferentially binds dendritic cells expressing DC-SIGN.Type: GrantFiled: March 30, 2012Date of Patent: December 4, 2012Assignee: Immune Design Corp.Inventors: Christopher James Nicolai, Semih Ullah Tareen
-
Patent number: 8318419Abstract: The present invention provides for testing methods to determine an effective testing agent that affects the activity of the HIV Gag protein at the plasma membrane of a cell, and specifically, effecting changes in the structural conformation of at least one fatty acid of PI(4,5)P2, a member of a family of differentially phosphorylated phosphatidylinositides, wherein inhibition of the extension of such fatty acid into the MA domain of the Gag protein reduces binding of Gag to the plasma membrane, thereby inhibiting virus particle assembly and subsequent replication of the HIV virus.Type: GrantFiled: July 18, 2008Date of Patent: November 27, 2012Assignee: University of Maryland, Baltimore CountyInventors: Michael F. Summers, Jamil S. Saad
-
Patent number: 8309098Abstract: The invention relates to novel insertion sites useful for the integration of HIV DNA sequences into the MVA genome, and to the resulting recombinant MVA derivatives.Type: GrantFiled: August 31, 2011Date of Patent: November 13, 2012Assignee: Bavarian Nordic A/SInventors: Paul Howley, Sonja Leyrer, Paul Chaplin, Eva Felder
-
Publication number: 20120276141Abstract: Provided herein are small molecule CD4 mimetics effective to bind to HIV Env proteins. A CD4 mimetic of the invention, when bound to an Env protein, is effective to induce a conformational change in the Env protein such that cyptic epitopes on the Env protein are exposed. Also provided herein are related methods of identifying and using such small molecule CD4 mimetics, for example, to elicit an immune response in a subject upon administration.Type: ApplicationFiled: June 8, 2012Publication date: November 1, 2012Inventors: Indresh K. Srivastava, Victoria Sharma, Susan W. Barnett, Jeffrey Ulmer
-
Publication number: 20120269851Abstract: The present invention relates to polynucleotides encoding immunogenic HIV polypeptides. Uses of the polypeptides in applications including immunization, generation of packaging cell lines, and production of HIV polypeptides are also described. Polynucleotides encoding antigenic HIV polypeptides are described, as are uses of these polynucleotides and polypeptide products therefrom, including formulations of immunogenic compositions and uses thereof.Type: ApplicationFiled: February 17, 2012Publication date: October 25, 2012Applicants: University of Stellenbosch, NOVARTIS VACCINES & DIAGNOSTICS, INC.Inventors: Jan zur Megede, Susan Barnett, Ying Lian, Susan Engelbrecht, Estrelita Janse van Rensburg, Thomas J. Scriba
-
Publication number: 20120269848Abstract: This invention relates to cholesterol-sequestering agents and methods of using cholesterol-sequestering agents to treat or prevent infection. The compositions of the invention can be used in vitro or in vivo to decrease the load of a microorganism in a biological sample. Methods of generating an immune response against a microorganism are also included.Type: ApplicationFiled: June 18, 2012Publication date: October 25, 2012Inventors: George A. Scheele, James E. Hildreth
-
Patent number: 8293465Abstract: The present invention relates to an antibody mimetic of carbohydrate binding module (CBM) which specifically binds to an epitope on HIV glycoprotein. The present invention also relates to a method of detecting HIV glycoprotein.Type: GrantFiled: April 6, 2010Date of Patent: October 23, 2012Assignee: National Tsing Hua UniversityInventors: Margaret Dah-Tsyr Chang, Yuan-Chuan Lee, Rong-Yuan Huang, Shu-Chuan Lin, Wei-I Chou, Shi-Hwei Liu
-
Publication number: 20120258135Abstract: The invention provides methods of formulating an anti-inflammatory composition for treating inflammatory conditions in a specific organ or tissue. The method involves selecting at least one pathogen that is pathogenic in the specific organ or tissue; producing an antigenic composition comprising antigenic determinants that together are specific for the pathogen; and formulating the antigenic composition for administration as an anti-inflammatory composition capable of eliciting an anti-inflammatory response in the specific organ or tissue. In embodiments of the invention the pathogen may be an endogenous pathogen, such as an endogenous bacterial pathogen. The pathogen may be an exogenous pathogen, such as a bacterial pathogen, viral pathogen, a fungal pathogen, or a helminth pathogen.Type: ApplicationFiled: January 26, 2012Publication date: October 11, 2012Inventors: Harold David Gunn, Salim Dhanji, Brett Anthony Premack, Michael Tak Huai Chow
-
Publication number: 20120251537Abstract: PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these PD-1 antagonists in conjunction with an antigen from the infectious agent or tumor. Thus, subjects with infections, such as persistent infections can be treated using PD-1 antagonists. In addition, subjects with tumors can be treated using the PD-1 antagonists. In several examples, subjects can be treated by transplanting a therapeutically effective amount of activated T cells that recognize an antigen of interest and by administering a therapeutically effective amount of a PD-1 antagonist.Type: ApplicationFiled: March 30, 2012Publication date: October 4, 2012Inventors: Rafi Ahmed, Rama Amara, Gordon Freeman, Arlene Sharpe
-
Publication number: 20120244182Abstract: The invention provides immunostimulatory compositions and methods of administration thereof. Also provided are methods of administering a tryptanthrin compound in an effective amount to enhance the immune response of a subject to an antigen. Also provided are methods of administering an effective amount of a tryptanthrin to stimulate the immune response in a subject for the treatment of cancer. Further provided are methods of administering a tryptanthrin compounds as an immunotherapeutic in the treatment of infectious diseases.Type: ApplicationFiled: June 4, 2012Publication date: September 27, 2012Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.Inventor: Nicholas M. VALIANTE
-
Publication number: 20120237544Abstract: The present invention relates to a method of coating a spore with one or more therapeutic agents. The present invention also relates to a coated spore obtained by the method of the present invention and the use of the coated spore as a vaccine.Type: ApplicationFiled: September 21, 2010Publication date: September 20, 2012Applicant: Royal Holloway and Bedford New CollegeInventors: Simon Michael Cutting, Hong Anh Huynh
-
Patent number: 8268323Abstract: Stabilized forms of gp120 polypeptide, nucleic acids encoding these stabilized forms, vectors comprising these nucleic acids, and methods of using these polypeptides, nucleic acids, vectors and host cells are disclosed. Crystal structures and computer systems including atomic coordinates for stabilized forms of gp120, and gp120 with an extended V3 loop, and methods of using these structures and computer systems are also disclosed.Type: GrantFiled: September 14, 2011Date of Patent: September 18, 2012Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, Dana Farber Cancer Institute, Inc.Inventors: Peter Kwong, John Mascola, Gary Nabel, Richard Wyatt, Barna Dey, Ling Xu, Tongqing Zhou, Joseph Sodroski, Wen Yuan, Shi-Hua Xiang
-
Publication number: 20120225093Abstract: The present invention relates to compositions and methods of treating, inhibiting, or controlling HIV infection.Type: ApplicationFiled: October 11, 2011Publication date: September 6, 2012Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEYInventors: Michael B. Mathews, Hartmut M. Hanauske-Abel, Tsafi Pe'ery, Mainul Hoque, Paul Palumbo, Deepti Saxena, Darlene D'Alliessi-Gandolfi, Myung-Hee Park
-
Publication number: 20120225083Abstract: The invention is directed to polypeptides and polypeptide fragments from HIV-1 envelope (Env) proteins following the characterization of Env structures from environments where HIV isolates expose conserved neutralization-sensitive Env structures. There is provided a polypeptide being all or a fragment of an HIV-1 envelope protein from a transmission strain of HIV-1, the polypeptide having neutralization sensitive epitopes that are accessible.Type: ApplicationFiled: September 16, 2009Publication date: September 6, 2012Applicants: THE UNIVERSITY OF MELBOURNE, THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH, NEWSOUTH INNOVATIONS PTY LIMITEDInventors: Damian Purcell, Robert Center, Sharmila Mohana Rama Reddy, Anthony Dominic Kelleher, David Albert Cooper, Paul Rene Gorry, Jasminka Sterjovski
-
Publication number: 20120219583Abstract: The invention is directed to a nucleic acid molecule encoding a HIV-1 polypeptide which comprises the nucleic acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4. The invention also provides a method of inducing an immune response against HIV-1 in a mammal.Type: ApplicationFiled: October 15, 2010Publication date: August 30, 2012Applicants: Los Alamos National Security, LLC, The U.S. of America, as rep. by the Sec., Dept. of HHSInventors: Gary J. Nabel, Zhi-Yong Yang, Wing-Pui Kong, Bette Korber
-
Publication number: 20120207765Abstract: A compound represented by general formula (I): a salt thereof, a solvate thereof, or a prodrug thereof wherein all symbols are as defined in the specification has an antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, systemic erythematosus, retinopathy, macular degeneration, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiac/vascular disease (for example, arteriosclerosis, myocardial infarction, stenocardia, cerebral infarction, chronic arterial occlusive disease, etc.), metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.Type: ApplicationFiled: March 8, 2012Publication date: August 16, 2012Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Masaya Kokubo, Hiroshi Ochiai, Yoshikazu Takaoka, Shiro Shibayama
-
Publication number: 20120207783Abstract: Provided herein are HIV vaccines comprising HIV polypeptide-encoding DNA adsorbed to PLG and/or HIV proteins. Also provided are methods of using these vaccines to generate immune responses in a subject.Type: ApplicationFiled: December 22, 2011Publication date: August 16, 2012Inventors: John DONNELLY, Susan W. BARNETT, Derek O'HAGAN
-
Publication number: 20120207784Abstract: Disclosed herein are isolated rubella viral vector constructs that include a rubella non-structural protein open reading frame (ORF) with an in-frame deletion, a rubella structural protein ORF, and a heterologous antigenic insert. In one example, the in-frame deletion within the rubella non-structural protein ORF is an in-frame deletion between two NotI restriction enzyme sites. In some examples, the heterologous antigenic insert is positioned within the rubella non-structural protein ORF. In other examples, the heterologous antigenic insert is positioned within the rubella structural protein ORF. Exemplary antigenic inserts include a Gag antigenic insert, a gp41 antigenic insert or a gp120 antigenic insert. Also disclosed are uses of the isolated rubella viral vector, such as to induce an immune response to HIV-1, testing sensitivity to neutralizing antibodies, or screening antiviral drugs (such as protease inhibitors).Type: ApplicationFiled: October 15, 2010Publication date: August 16, 2012Inventors: Ira Berkower, Angelo Spadaccini
-
Patent number: 8236324Abstract: An HIV-1 type (or subtype) O retrovirus protein, or a natural or synthetic polypeptide or peptide including at least a part of said protein, which is capable of being recognized by antibodies isolated from a serum resulting from infection by an HIV-1 type O VAU strain or an HIV-1 type (or subtype) O DUR strain.Type: GrantFiled: November 2, 2006Date of Patent: August 7, 2012Assignee: Institut PasteurInventors: Pierre Charneau, François Clavel, Andrew Borman, Caroline Quillent, Denise Guetard, Luc Montagnier, Jacqueline Donjon de Saint-Martin, Jacques Cohen
-
Publication number: 20120195852Abstract: Improved vaccines which include a nucleotide sequence that encodes immunomodulating protein operably linked to regulatory elements are disclosed. The improved vaccines include DNA vaccines, recombinant vaccines for delivering foreign antigen and live attenuated vaccines. Methods of immunizing individuals are disclosed. Compositions for and methods of treating individuals with autoimmune diseases are disclosed.Type: ApplicationFiled: January 27, 2012Publication date: August 2, 2012Inventors: David B. Weiner, Jong J. Kim, Jeong-Im Sin
-
Publication number: 20120195928Abstract: Compositions comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with one or more of CTACK protein, TECK protein, MEC protein and functional fragments thereof and/or an isolated nucleic acid molecule that encodes a protein selected from the group consisting of: CTACK, TECK, MEC and functional fragments thereof are disclosed. Methods of inducing an immune response, including methods of inducing mucosal immune responses, in an individual against an immunogen, using such compositions are disclosed.Type: ApplicationFiled: October 28, 2011Publication date: August 2, 2012Inventors: David B. Weiner, Michele Kutzler
-
Publication number: 20120189657Abstract: The present invention includes cold-adapted, acid-fast bacterium for use as a vaccine and a vaccine vector. In preferred embodiments, the cold-adapted, acid-fast bacterium is a Mycobacteria, for example, Mycobacteria shottsii.Type: ApplicationFiled: March 30, 2012Publication date: July 26, 2012Applicant: University of Georgia Research Foundation, Inc.Inventors: Frederick Quinn, Candace McCombs, Russell K. Karls
-
Patent number: 8226955Abstract: Env-CD4 polypeptide complexes and hybrids that expose cryptic epitopes important in virus neutralization are disclosed. Method of diagnosis, treatment and prevention using the polypeptides are also provided.Type: GrantFiled: August 19, 2010Date of Patent: July 24, 2012Assignee: Novartis Vaccines & Diagnostics, IncInventors: Susan W Barnett, Indresh K Srivastava
-
Publication number: 20120183557Abstract: Hybrid molecules comprising CD4 minimal modules or mimetics that bind to HIV Env polypeptides in combination with one or more HIV Tat polypeptides are described. Also described are complexes of these hybrid molecules with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides.Type: ApplicationFiled: March 22, 2012Publication date: July 19, 2012Applicant: NOVARTIS VACCINES AND DIAGNOSTICS. INC.Inventors: Susan BARNETT, Rino RAPPUOLI, Victoria A. SHARMA, Indresh K. SRIVASTAVA, Jan ZUR MEGEDE
-
Publication number: 20120183597Abstract: The present invention relates, in general, to human immunodeficiency virus (HIV), and, in particular, to a method of inducing neutralizing antibodies to HIV and to compounds and compositions suitable for use in such a method.Type: ApplicationFiled: October 4, 2011Publication date: July 19, 2012Applicant: DUKE UNIVERSITYInventors: Barton F. Haynes, S. Munir Alam, Hua-Xin Liao
-
Publication number: 20120177677Abstract: Provided are peptide vaccines including the signal peptide domain of selected target antigens of intracellular pathogens. The peptide vaccines of the invention contain multiple class II and class I-restricted epitopes and are recognized and presented by the majority of the vaccinated human population. Further provided, in particular, are anti tuberculosis vaccines. Also further provided are compositions including the vaccines as well as their use to treat or prevent infection.Type: ApplicationFiled: July 15, 2010Publication date: July 12, 2012Applicant: VAXIL BIOTHERAPEUTICS LTD.Inventor: Lior Carmon